Abstract

This is a non-randomized study to estimate the frequency of eradication of MAC in previously MAC-infected individuals with a adequate response to antiretroviral therapy. Subjects must be diagnosed with MAC, be treated with a macrolide-based regimen for one year, have CD4 counts >100 cells/mm3, and currently be receiving antiretroviral therapy for at least 16 weeks. The primary objective is to determine if anti-mycobacterial therapy can be withdrawn from these subjects and to estimate the duration of time these subjects remain free from MAC infection. The secondary objectives are to determine if the profile of host immune cells and cytokine responses in the blood (TH1 and TH2) predict risk of recurrent MAC disease in subjects who are withdrawn from anti-mycobacterial therapy and remain free from disease with subjects who are withdrawn from therapy and have recurrence of disease. In vitro responses to three different MAC antigens will be compared to determine which, if any, are best predictive of low vs. high risk of MAC disease in this population. Delayed type hypersensitivity skin test responses will be determined to see if they can be used to predict risk for MAC infection after discontinuation of anti-mycobacterial therapy. The study will also determine if frozen PBMC's can be used in lyphocyte proliferation assays as predictors of clinical outcome.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000096-39
Application #
6412390
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
1975-10-01
Project End
2003-11-30
Budget Start
Budget End
Support Year
39
Fiscal Year
2000
Total Cost
Indirect Cost

  Institution

Name
New York University
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10016

  Publications

Jun, Gyungah R; Chung, Jaeyoon; Mez, Jesse et al. (2017) Transethnic genome-wide scan identifies novel Alzheimer's disease loci. Alzheimers Dement 13:727-738
Homann, O R; Misura, K; Lamas, E et al. (2016) Whole-genome sequencing in multiplex families with psychoses reveals mutations in the SHANK2 and SMARCA1 genes segregating with illness. Mol Psychiatry 21:1690-1695
Ridge, Perry G; Hoyt, Kaitlyn B; Boehme, Kevin et al. (2016) Assessment of the genetic variance of late-onset Alzheimer's disease. Neurobiol Aging 41:200.e13-200.e20
Hohman, Timothy J; Bush, William S; Jiang, Lan et al. (2016) Discovery of gene-gene interactions across multiple independent data sets of late onset Alzheimer disease from the Alzheimer Disease Genetics Consortium. Neurobiol Aging 38:141-150
Jun, G; Ibrahim-Verbaas, C A; Vronskaya, M et al. (2016) A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry 21:108-17
Ebbert, Mark T W; Boehme, Kevin L; Wadsworth, Mark E et al. (2016) Interaction between variants in CLU and MS4A4E modulates Alzheimer's disease risk. Alzheimers Dement 12:121-129
Hohman, Timothy J; Cooke-Bailey, Jessica N; Reitz, Christiane et al. (2016) Global and local ancestry in African-Americans: Implications for Alzheimer's disease risk. Alzheimers Dement 12:233-43
Li, Yi; Tsui, Wai; Rusinek, Henry et al. (2015) Cortical laminar binding of PET amyloid and tau tracers in Alzheimer disease. J Nucl Med 56:270-3
Ghani, Mahdi; Reitz, Christiane; Cheng, Rong et al. (2015) Association of Long Runs of Homozygosity With Alzheimer Disease Among African American Individuals. JAMA Neurol 72:1313-23
Beecham, Gary W; Dickson, Dennis W; Scott, William K et al. (2015) PARK10 is a major locus for sporadic neuropathologically confirmed Parkinson disease. Neurology 84:972-80

Showing the most recent 10 out of 470 publications